相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1973
招募中
1
100.0%
暂无批准数据
- Portage Biotech's selective Adenosine A2B receptor inhibitor PORT-7 demonstrated significant single-agent activity and over 90% tumor growth inhibition when combined with anti-PD1 antibody in murine mesothelioma models. - The preclinical results, presented at the 2025 European Lung Cancer Congress, revealed significant infiltration of CD3 and CD45 positive immune effector cells, marking the first reported antitumor activity against mesothelioma using a selective A2B receptor inhibitor. - Portage plans to commence first-in-human trials with PORT-7 and eventually combine it with PORT-6 (an A2A adenosine receptor inhibitor) in the ongoing ADPORT-601 trial to achieve complete blockade of adenosine-induced immunosuppression.
• Adenosine antagonists are under investigation for novel therapeutic applications in neurodegenerative diseases, oncology, and cardiovascular disorders. • Several companies, including Arcus Biosciences and Corvus Pharmaceuticals, are advancing adenosine antagonists through clinical trials to improve treatment landscapes. • Clinical trials are evaluating drugs like etrumadenant, ciforadenant and PBF-680 in various phases for conditions like colorectal cancer, prostate cancer and COPD.
